Goldman Sachs
-
-
Corporate borrowers are pumping out new bonds this week and on Thursday it was the turn of some of those worst hit by the Covid-19 pandemic, as investors have felt emboldened enough to look further down the credit curve each day this week. Aeroports de Paris is on screens, as investors credited central bank intervention with bolstering the market. -
European issuers have got their wish thanks to deals from European Investment Bank at three years and a five year from KfW on Wednesday.
-
The Republic of Austria and the African Development Bank announced new bond transactions on Wednesday which will be used to provide emergency financing in response to the coronavirus outbreak.
-
The Republic of Slovenia navigated a much changed euro new issue market on Tuesday, executing a three year bond and tap that required unconventional pricing tactics.
-
Diageo, the UK distiller and brewer, poured a triple tranche trade into Tuesday's busy primary corporate bond market, as syndicate bankers said the high grade companies on screen were the some of the best names to raise spirits.
-
Chinese biotechnology company InnoCare Pharma’s shares surged over 10% on their Monday debut, following an online opening ceremony for the HK$2.2bn ($288.7m) listing in Hong Kong.
-
Europe’s corporate bond new issue market burst back into life on Friday after a nine day coma with two emphatic, big, generously priced deals from impeccable issuers — exactly the pattern of issuance, although on a smaller scale, that the US market has produced on three days this week. Engie and Unilever raised €4.5bn between them, most of it from investors working at home amid coronavirus quarantines.
-
Despite the terrible effects of the coronavirus pandemic on capital markets, the MTN market is open and functioning.
-
Goldman Sachs announced on Thursday that an employee in its investment banking division in Hong Kong had been identified as a "highly probable case" of the Covid-19 coronavirus.
-
David Binnion, co-head of equity capital markets for Asia ex-Japan at Goldman Sachs, is retiring after 15 years at the firm, according to a memo seen by GlobalCapital Asia.
-
Chinese biotechnology firm InnoCare Pharma has priced its HK$2.2bn ($288m) IPO at the top of the marketed range, following solid demand from institutional and retail investors, according to bankers close to the deal.
